sars-cov-2 surrogate virus neutralization test (svnt) by genscript cpass tm sars-cov-2 neutralization antibody detection kit  (GenScript corporation)

Journal: Vaccines

Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

doi: 10.3390/vaccines10122063

Figure Lengend Snippet: Longitudinal measurements of neutralizing antibodies in different groups of severity. Lineplot representing inhibition percentage kinetics of neutralizing antibodies through four longitudinal measurements. Each point represents the median neutralization value with standard error for that follow-up. The non-hospitalized group is represented by the orange line, the blue line represents recovered hospitalized patients, and the purple line represents deceased hospitalized patients.

Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

Techniques: Inhibition, Neutralization

Journal: Vaccines

Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

doi: 10.3390/vaccines10122063

Figure Lengend Snippet: Longitudinal measurements of total anti-N antibodies in different groups of severity. Lineplot representing total anti-N antibody concentration through four longitudinal measurements. Each point represents the median neutralization value with standard error for that follow-up. The non-hospitalized patients group is represented by the orange line, the blue line represents recovered hospitalized patients, and the purple line represents deceased hospitalized patients.

Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

Techniques: Concentration Assay, Neutralization

Journal: Vaccines

Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

doi: 10.3390/vaccines10122063

Figure Lengend Snippet: Proportion of patients in each neutralization category. Barplots show the proportion of patients with the different antibody classifications in each follow-up and within study groups (non-hospitalized, recovered, and deceased). Neutralization categories: 0–30% negative production, 31–60% low production, 61–90% medium production, and >90% high production. Initial measurement stands for the first follow-up measurement in a period of <14 days post-symptom onset, follow-up 1 for the period between 14 and 21 days post-symptom onset, follow-up 2 for the period between 22 and 30 days post-symptom onset, and follow-up 3 for the last measurement 30 days post-symptom onset. * = p < 0.05, *** = p < 0.0001.

Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

Techniques: Neutralization

Journal: Vaccines

Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

doi: 10.3390/vaccines10122063

Figure Lengend Snippet: ( A , B ). Antibody titers and survival analysis. Kaplan–Meier Curves coupled with the Cox test was constructed to evaluate survival probability according to the neutralization categories (low, medium, and high) and the total anti-N antibody titers (low and high). ( A ): Kaplan–Meier curve showing the neutralization categories in which patients were classified in their initial measurement and the decrease in survival probability in patients with a negative or low antibody production. ( B ): Kaplan–Meier curve showing the total anti-N production classification (high and low) in which patients were classified in their initial measurement and the decrease in survival probability in patients with a low total anti-N antibody production. ( A ) p = 0.00025, ( B ) p = 0.0359.

Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

Techniques: Construct, Neutralization

Journal: Vaccines

Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

doi: 10.3390/vaccines10122063

Figure Lengend Snippet: Longitudinal measurement of neutralizing antibodies according to viral lineage. Each point represents the median neutralization value with standard error for that follow-up measurement. Wuhan-like lineages are represented by the orange line, the green line represents patients infected with lineage B.1.1.519, the blue line represents patients infected with VOC Delta, and the purple line represents patients infected with Omicron.

Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

Techniques: Neutralization, Infection

Journal: Vaccines

Article Title: Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes

doi: 10.3390/vaccines10122063

Figure Lengend Snippet: Proportion of patients in each neutralization category barplot collage with four panels, one panel for each of the longitudinal measurements showing the proportion of patients classified according to the following neutralization categories: 0–30% negative production, 31–60% low production, 61–90% medium production, and >90% high production of each viral lineage (Wuhan-WT, B.1.1.519, and VOC Delta). Initial measurement represents a period of <14 days post-symptom onset, follow-up 1 to the period between 14 and 21 days post-symptom onset, follow up-2 to the period between 22 and 30 days post-symptom onset, and follow-up 3 the last measurement (30 days post-symptom onset). * = p < 0.05, *** = p < 0.001.

Article Snippet: Neutralization antibodies were detected using a surrogate virus neutralization test (Genscript cPass SARS-CoV-2 Neutralization Antibody Detection, Piscatawa, NJ, USA) following the manufacturer’s recommendations.

Techniques: Neutralization